Base de dados : MEDLINE
Pesquisa : C04.557.386 [Categoria DeCS]
Referências encontradas : 45296 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 4530 ir para página                         

  1 / 45296 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29505542
[Au] Autor:Shi Z; Ding H; Shen QW; Lu XG; Chen JY; Chen X; Tang X
[Ad] Endereço:Department of Medical Oncology.
[Ti] Título:The clinical manifestation, survival outcome and predictive prognostic factors of 137 patients with primary gastrointestinal lymphoma (PGIL): Strobe compliant.
[So] Source:Medicine (Baltimore);97(1):e9583, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This retrospective study aimed to investigate clinical characteristics and prognostic factors in patients with primary gastrointestinal lymphoma (PGIL) of Chinese population.From January 2001 to December 2015, 137 patients diagnosed with PGIL were recruited. The clinical features, treatment, and follow-up information were analysed.The median patient age was 62.3 years. With 18.47 months follow-up, the 2-year progress-free survival and overall survival rate was 74.9% and 75.5%, respectively. The overall response rate was 33.6%. Age≥60 years, advanced Lugano staging (≥stage IIE), elevated lactate dehydrogenase (LDH) levels, ≥2 extra-nodal involved sites, National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)≥4, Ki-67≥50% were associated with worse prognosis in univariate analysis (P < .05). By multivariate analyses, we determined that the involvement of extra-nodal involved sites was the only statistically significant poor prognostic factor in PGIL.Age, staging, LDH levels, NCCN-IPI, Ki-67 especially involvement of multiple extra-nodal sites were associated with poor overall survival of PGIL.
[Mh] Termos MeSH primário: Neoplasias Gastrointestinais/mortalidade
Linfoma/mortalidade
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica
China/epidemiologia
Feminino
Neoplasias Gastrointestinais/diagnóstico
Neoplasias Gastrointestinais/patologia
Neoplasias Gastrointestinais/terapia
Trato Gastrointestinal/patologia
Seres Humanos
Linfoma/diagnóstico
Linfoma/patologia
Linfoma/terapia
Masculino
Meia-Idade
Estudos Retrospectivos
Análise de Sobrevida
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009583


  2 / 45296 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480866
[Au] Autor:Ubukata M; Hara M; Nishizawa Y; Fujii T; Nitta K; Ohta A
[Ad] Endereço:Division of Nephrology, Department of Medicine, Tokyo Metropolitan Komagome Hospital, Bunkyo-Ku.
[Ti] Título:Prevalence and mortality of chronic kidney disease in lymphoma patients: A large retrospective cohort study.
[So] Source:Medicine (Baltimore);97(2):e9615, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In patients with lymphoma, an important issue that has been recognized is renal involvement, including glomerulonephritis, acute kidney injury, and lymphoma infiltrating the kidney. However, the prevalence and mortality of chronic kidney disease (CKD) have not been fully understood in lymphoma patients. This study aimed to evaluate the prevalence of CKD and its impact on mortality in those patients.This was a retrospective cohort study of 429 consecutive lymphoma patients who were admitted or regularly visited our hospital from January 2013 to October 2016. CKD was defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m and/or proteinuria ≥ 1+ that was sustained for at least 3 months. The prevalence of CKD at enrollment was evaluated according to the modified CKD classification by Kidney Disease: Improving Global Outcomes (KDIGO) (eGFR and proteinuria category). Dipstick proteinuria was classified into 3 grades: A1 for - and ±; A2 for 1+ or 2+; and A3 for ≥3+. The eGFR (mL/min/1.73 m) was classified into 6 stages: G1 for ≥90, G2 for 60 to 89, G3a for 45 to 59, G3b for 30 to 44, G4 for 15 to 29, and G5 for <15. The cumulative mortality rate was estimated using the Kaplan-Meier method, with stratification into 2 groups based on the presence or absence of CKD. Furthermore, a multivariate Cox proportional hazards regression model was used to calculate the hazard ratio (HR) and its 95% confidence interval (CI) for all-cause mortality, after adjustments for age, sex, pathologic type, clinical stage of lymphoma, presence or absence of diabetes mellitus, hypertension, and cardiovascular disease.The mean follow-up period was 3.06 ±â€Š0.96 years, and the prevalence of CKD at study enrollment was 34.5%. The cumulative mortality rate was 20.7%, and was significantly higher in the CKD group than in the group without CKD (36.4% vs 18.0%, P = .02). Multivariate analysis found mortality to be significantly associated with CKD (HR 1.58; 95% CI, 1.01-2.46), and this association was the most robust with very high-risk CKD (HR 6.94; 95% CI, 2.50-17.33).The prevalence of CKD in lymphoma patients was high. CKD should be considered an independent risk factor for mortality among patients with lymphoma.
[Mh] Termos MeSH primário: Linfoma/complicações
Linfoma/mortalidade
Insuficiência Renal Crônica/complicações
Insuficiência Renal Crônica/mortalidade
[Mh] Termos MeSH secundário: Comorbidade
Feminino
Seguimentos
Seres Humanos
Estimativa de Kaplan-Meier
Linfoma/fisiopatologia
Masculino
Meia-Idade
Análise Multivariada
Prevalência
Modelos de Riscos Proporcionais
Insuficiência Renal Crônica/fisiopatologia
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009615


  3 / 45296 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29480830
[Au] Autor:Conte C; Palmaro A; Grosclaude P; Daubisse-Marliac L; Despas F; Lapeyre-Mestre M
[Ad] Endereço:LEASP-UMR 1027, Inserm-University of Toulouse.
[Ti] Título:A novel approach for medical research on lymphomas: A study validation of claims-based algorithms to identify incident cases.
[So] Source:Medicine (Baltimore);97(2):e9418, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The use of claims database to study lymphomas in real-life conditions is a crucial issue in the future. In this way, it is essential to develop validated algorithms for the identification of lymphomas in these databases. The aim of this study was to assess the validity of diagnosis codes in the French health insurance database to identify incident cases of lymphomas according to results of a regional cancer registry, as the gold standard.Between 2010 and 2013, incident lymphomas were identified in hospital data through 2 algorithms of selection. The results of the identification process and characteristics of incident lymphomas cases were compared with data from the Tarn Cancer Registry. Each algorithm's performance was assessed by estimating sensitivity, predictive positive value, specificity (SPE), and negative predictive value.During the period, the registry recorded 476 incident cases of lymphomas, of which 52 were Hodgkin lymphomas and 424 non-Hodgkin lymphomas. For corresponding area and period, algorithm 1 provides a number of incident cases close to the Registry, whereas algorithm 2 overestimated the number of incident cases by approximately 30%. Both algorithms were highly specific (SPE = 99.9%) but moderately sensitive. The comparative analysis illustrates that similar distribution and characteristics are observed in both sources.Given these findings, the use of claims database can be consider as a pertinent and powerful tool to conduct medico-economic or pharmacoepidemiological studies in lymphomas.
[Mh] Termos MeSH primário: Algoritmos
Bases de Dados Factuais
Seguro Saúde
Linfoma/diagnóstico
Sistema de Registros
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Pesquisa Biomédica/métodos
Feminino
Seres Humanos
Linfoma/terapia
Masculino
Meia-Idade
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; VALIDATION STUDIES
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180227
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009418


  4 / 45296 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773462
[Au] Autor:Yu L; Li L; Medeiros LJ; Young KH
[Ad] Endereço:Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
[Ti] Título:NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.
[So] Source:Blood Rev;31(2):77-92, 2017 Mar.
[Is] ISSN:1532-1681
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The NF-κB pathway, a critical regulator of apoptosis, plays a key role in many normal cellular functions. Genetic alterations and other mechanisms leading to constitutive activation of the NF-κB pathway contribute to cancer development, progression and therapy resistance by activation of downstream anti-apoptotic pathways, unfavorable microenvironment interactions, and gene dysregulation. Not surprisingly, given its importance to normal and cancer cell function, the NF-κB pathway has emerged as a target for therapy. In the review, we present the physiologic role of the NF-κB pathway and recent advances in better understanding of the pathologic roles of the NF-κB pathway in major types of lymphoid neoplasms. We also provide an update of clinical trials that use NF-κB pathway inhibitors. These trials are exploring the clinical efficiency of combining NF-κB pathway inhibitors with various agents that target diverse mechanisms of action with the goal being to optimize novel therapeutic opportunities for targeting oncogenic pathways to eradicate cancer cells.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Leucemia Linfoide/tratamento farmacológico
Leucemia Linfoide/metabolismo
Linfoma/tratamento farmacológico
Linfoma/metabolismo
Terapia de Alvo Molecular
NF-kappa B/metabolismo
Transdução de Sinais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacologia
Biomarcadores Tumorais
Ensaios Clínicos como Assunto
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Leucemia Linfoide/diagnóstico
Leucemia Linfoide/etiologia
Tecido Linfoide/efeitos dos fármacos
Tecido Linfoide/metabolismo
Tecido Linfoide/patologia
Linfoma/diagnóstico
Linfoma/etiologia
Mutação
Resultado do Tratamento
Microambiente Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (NF-kappa B)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  5 / 45296 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29342201
[Au] Autor:Neska-Matuszewska M; Bladowska J; Sasiadek M; Zimny A
[Ad] Endereço:Department of General and Interventional Radiology and Neuroradiology, Wroclaw Medical University, Wroclaw, Poland.
[Ti] Título:Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-Searching for a practical approach.
[So] Source:PLoS One;13(1):e0191341, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In conventional MR examinations glioblastomas multiforme (GBMs), metastases and primary CNS lymphomas (PCNSLs) may show very similar appearance. The aim of the study was to evaluate usefulness of multiparametric T2*DSC perfusion and diffusion MR imaging in the preoperative differentiation of these tumors. MATERIAL AND METHODS: Seventy four solitary enhancing tumors (27 GBMs, 30 metastases, 17 PCNSLs) were enrolled in the study. Parameters of cerebral blood volume (rCBV), peak height (rPH), percentage of signal recovery (rPSR) and apparent diffusion coefficient (ADC) were assessed from the tumor core and the peritumoral non-enhancing T2-hyperintense zone. RESULTS: Within the tumor core there were no differences in perfusion and diffusion parameters between GBMs and metastases. Compared to GBMs and metastases, PCNSLs showed significantly lower rCBV and rPH, ADC as well as higher rPSR values. Max rCBV with a cut-off value of 2.18 demonstrated the highest accuracy of 0.98 in differentiating PCNSLs from other tumors. To distinguish GBMs from metastases analysis of the peritumoral zone was performed showing significantly higher rCBV, rPH and lower ADC values in GBMs with the highest accuracy of 0.94 found for max rCBV at a cut-off value of 0.98. CONCLUSIONS: Max rCBV seems to be the most important parameter to differentiate GBMs, metastases and PCNSLs. Analysis of max rCBV within the tumor core enables to distinguish hypoperfused PCNSLs from hyperperfused GBMs and metastases while evaluation of max rCBV within the peritumoral zone is helpful to distinguish GBMs showing peritumoral infiltration from metastases surrounded by pure edema.
[Mh] Termos MeSH primário: Glioblastoma/diagnóstico por imagem
Angiografia por Ressonância Magnética/métodos
[Mh] Termos MeSH secundário: Idoso
Volume Sanguíneo/fisiologia
Neoplasias Encefálicas/patologia
Diferenciação Celular/genética
Neoplasias do Sistema Nervoso Central
Circulação Cerebrovascular/fisiologia
Diagnóstico Diferencial
Imagem de Difusão por Ressonância Magnética/métodos
Feminino
Glioblastoma/diagnóstico
Glioblastoma/genética
Seres Humanos
Linfoma/diagnóstico por imagem
Linfoma/metabolismo
Masculino
Meia-Idade
Metástase Neoplásica
Sistema Nervoso/patologia
Perfusão
Curva ROC
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191341


  6 / 45296 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29284778
[Au] Autor:Caballero-Hernandez D; Najera-Valderrabano D; Valadez-Lira A; Franco-Molina M; Gomez-Flores R; Tamez-Guerra P; Tamez-Guerra R; Rodríguez-Padilla C
[Ad] Endereço:Department of Microbiology and Immunology, Laboratory of Immunology and Virology, Faculty of Biological Sciences, Autonomous University of Nuevo León, San Nicolás de los Garza, NL 66455, Mexico.
[Ti] Título:Alterations of antitumor and metabolic responses in L5178Y-R lymphoma-bearing mice after only 30-minute daily chronic stress exposure.
[So] Source:Exp Oncol;39(4):276-280, 2017 Dec.
[Is] ISSN:1812-9269
[Cp] País de publicação:Ukraine
[La] Idioma:eng
[Ab] Resumo:AIM: In stress research, reducing times of stress induction may contribute to improving the well-being of experimental animals, especially in cancer models, already under physiological distress. To support this idea, we evaluated the effects of a short-timed stress protocol on endocrine, metabolic and immune indicators in mice bearing the L5178Y-R lymphoma. MATERIALS AND METHODS: A 30-minute daily stress protocol was applied for 28 days to healthy and lymphoma-bearing BALB/c mice; body weight, plasma levels of corticosterone, norepinephrine, Th1/Th2 cytokines, insulin, and leptin, were measured. RESULTS: We found a 12% significant decrease in body weight in non-tumor bearing mice under stress (p < 0.007). The disruption of weight evolution was accompanied by a stress induced 85% decrease in plasmatic leptin (p < 0.01) and total reduction of insulin. Tumor burden alone was associated to an increase in more than two-fold of plasmatic levels of norepinephrine (p < 0.008). Neither stress nor tumor or their combination, resulted in an elevation of systemic IL-6. IFN-γ levels were 20 times higher in lymphoma-bearing animals when compared with non-tumor bearing mice (p < 0.01); however, under stress, this response was reduced by half, indicating a suppressing effect of chronic stress on the antitumor immune response. CONCLUSION: A short-timed stress induction is enough to cause significant alterations in the metabolism and immunity of healthy and tumor-bearing mice, supporting the use of short-timed protocols as an efficient way to induce chronic stress that also considers concerns regarding the well-being of experimental animals in biomedical research.
[Mh] Termos MeSH primário: Linfoma/imunologia
Linfoma/metabolismo
Estresse Fisiológico/fisiologia
[Mh] Termos MeSH secundário: Animais
Feminino
Camundongos
Camundongos Endogâmicos BALB C
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171230
[St] Status:MEDLINE


  7 / 45296 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29193021
[Au] Autor:Flinn IW; Thompson DS; Boccia RV; Miletello G; Lipman A; Flora D; Cuevas D; Papish SW; Berdeja JG
[Ad] Endereço:Sarah Cannon Research Institute/Tennessee Oncology PLLC, Nashville, TN, USA.
[Ti] Título:Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
[So] Source:Br J Haematol;180(3):365-373, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:This Phase II trial evaluated the efficacy of bendamustine, bortezomib and rituximab in patients with previously untreated low-grade lymphoma. Eligible patients had low grade lymphoma with no previous systemic disease treatment. Treatment for all patients was given in 28-day cycles for a maximum of 6 cycles. Patients received rituximab 375 mg/m intravenously (IV) on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6; bendamustine 90 mg/m IV on days 1 and 2; and bortezomib 1·6 mg/m IV on days 1, 8 and 15. Patients were permitted to begin maintenance treatment with rituximab 6 months after completion of study treatment and after 6-month follow-up assessments had been conducted. Fifty-four eligible patients were enrolled. The most common grade 3/4 toxicities were leucopenia (28%), neutropenia (30%) and lymphopenia (17%). There were no treatment-related deaths and 1 unrelated death on study (embolic stroke). The overall response rate was 94% for all patients. The median follow-up was 54 months. Kaplan-Meier estimates of progression-free survival and overall survival at 36 months were 75% and 88%, respectively. The treatment regimen was well tolerated and produced high response rates. Further study of this regimen in patients with previously untreated lymphoma is warranted.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Linfoma/tratamento farmacológico
Linfoma/patologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
Cloridrato de Bendamustina/administração & dosagem
Bortezomib/administração & dosagem
Feminino
Seres Humanos
Linfoma/mortalidade
Masculino
Meia-Idade
Gradação de Tumores
Estadiamento de Neoplasias
Indução de Remissão
Rituximab/administração & dosagem
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
4F4X42SYQ6 (Rituximab); 69G8BD63PP (Bortezomib); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.15044


  8 / 45296 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28450433
[Au] Autor:Alcaide-Leon P; Dufort P; Geraldo AF; Alshafai L; Maralani PJ; Spears J; Bharatha A
[Ad] Endereço:From the Departments of Medical Imaging (P.A.-L., A.B.) paulaalcaideleon@hotmail.com.
[Ti] Título:Differentiation of Enhancing Glioma and Primary Central Nervous System Lymphoma by Texture-Based Machine Learning.
[So] Source:AJNR Am J Neuroradiol;38(6):1145-1150, 2017 Jun.
[Is] ISSN:1936-959X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND PURPOSE: Accurate preoperative differentiation of primary central nervous system lymphoma and enhancing glioma is essential to avoid unnecessary neurosurgical resection in patients with primary central nervous system lymphoma. The purpose of the study was to evaluate the diagnostic performance of a machine-learning algorithm by using texture analysis of contrast-enhanced T1-weighted images for differentiation of primary central nervous system lymphoma and enhancing glioma. MATERIALS AND METHODS: Seventy-one adult patients with enhancing gliomas and 35 adult patients with primary central nervous system lymphomas were included. The tumors were manually contoured on contrast-enhanced T1WI, and the resulting volumes of interest were mined for textural features and subjected to a support vector machine-based machine-learning protocol. Three readers classified the tumors independently on contrast-enhanced T1WI. Areas under the receiver operating characteristic curves were estimated for each reader and for the support vector machine classifier. A noninferiority test for diagnostic accuracy based on paired areas under the receiver operating characteristic curve was performed with a noninferiority margin of 0.15. RESULTS: The mean areas under the receiver operating characteristic curve were 0.877 (95% CI, 0.798-0.955) for the support vector machine classifier; 0.878 (95% CI, 0.807-0.949) for reader 1; 0.899 (95% CI, 0.833-0.966) for reader 2; and 0.845 (95% CI, 0.757-0.933) for reader 3. The mean area under the receiver operating characteristic curve of the support vector machine classifier was significantly noninferior to the mean area under the curve of reader 1 ( = .021), reader 2 ( = .035), and reader 3 ( = .007). CONCLUSIONS: Support vector machine classification based on textural features of contrast-enhanced T1WI is noninferior to expert human evaluation in the differentiation of primary central nervous system lymphoma and enhancing glioma.
[Mh] Termos MeSH primário: Algoritmos
Neoplasias do Sistema Nervoso Central/diagnóstico
Glioma/diagnóstico
Linfoma/diagnóstico
Máquina de Vetores de Suporte
[Mh] Termos MeSH secundário: Adulto
Diagnóstico Diferencial
Feminino
Glioma/patologia
Seres Humanos
Aumento da Imagem/métodos
Interpretação de Imagem Assistida por Computador/métodos
Imagem por Ressonância Magnética/métodos
Masculino
Meia-Idade
Curva ROC
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.3174/ajnr.A5173


  9 / 45296 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29388203
[Au] Autor:Boutault R; Le Glaunec J; Debord C; Robillard N; Nicolet L; Eveillard M
[Ad] Endereço:Haematology Laboratory, Nantes University Hospital, Nantes, France.
[Ti] Título:Diagnosis of a lymphoma associated with human herpes virus 8 aided by flow cytometric immunophenotyping.
[So] Source:Br J Haematol;180(4):471, 2018 02.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Citometria de Fluxo
Infecções por Herpesviridae/complicações
Herpesvirus Humano 8
Imunofenotipagem
Linfoma/diagnóstico
Linfoma/etiologia
[Mh] Termos MeSH secundário: Adulto
Biomarcadores
Biópsia
Coinfecção
Citometria de Fluxo/métodos
Infecções por HIV
Infecções por Herpesviridae/virologia
Seres Humanos
Imunofenotipagem/métodos
Masculino
Tomografia Computadorizada por Raios X
Carga Viral
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14968


  10 / 45296 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384853
[Au] Autor:Chen X; Li H; Wang F; Liu H
[Ad] Endereço:Department of General Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning Province, China.
[Ti] Título:Early detection and integral resection are keys to extend survival in patients suffered from primary angiosarcoma of the spleen: A care-compliant case report and literature review.
[So] Source:Medicine (Baltimore);97(5):e9718, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Primary angiosarcoma of the spleen (PAS) is a very rare malignant neoplasm that originates from endothelial cells of the splenic blood vessels. Without typical clinical presentations and specific radiological features, PAS is very difficult to be early identified and 1-year mortality is extremely high. Late detection and spleen rupture are considered as the most important risk factors for early metastasis. PATIENT CONCERNS: Without any obvious symptom, a 35-year-old woman was admitted with splenic neoplasm that was accidentally discovered through a routine physical examination. DIAGNOSES: The patient was first diagnosed as lymphoma by laboratory tests and imaging studies, but changed to PAS by histological examinations after the surgery. INTERVENTIONS: After careful preoperational assessment, a laparoscopic-assisted splenectomy was scrutinously performed and the entire spleen was removed without any rupture. OUTCOMES: The postoperative followed-up was uneventful until 3 years later, when she sought medical attention due to persisting back pain. Bone metastasis was consequently identified and the symptom was quickly alleviated after radiation therapy. However, intra-abdominal metastases leading to intestinal obstruction occurred 4.5 years after surgery. Following short palliative treatment, the patient passed away 4 years and 9 months after the operation due to multiple organ failure. LESSONS: PAS is an uncommon and aggressive splenic disease. Once suspected, PAS require prompt and precise surgical procedures to remove the tumor origin. Laparoscopic-assisted splenectomy was technically feasible and therapeutically harmless for PAS treatment compared with open surgery as long as the spleen was removed intact. However, more evaluation of this option will be needed due to limited experience by now. Early discovery, precautious plan, meticulous operation, close follow-up, and comprehensive treatment may significantly prolong the living period of this fatal disease.
[Mh] Termos MeSH primário: Hemangiossarcoma/diagnóstico
Hemangiossarcoma/cirurgia
Neoplasias Esplênicas/diagnóstico
Neoplasias Esplênicas/cirurgia
[Mh] Termos MeSH secundário: Adulto
Diagnóstico Diferencial
Diagnóstico Precoce
Evolução Fatal
Feminino
Hemangiossarcoma/patologia
Hemangiossarcoma/radioterapia
Seres Humanos
Achados Incidentais
Linfoma/diagnóstico
Neoplasias Esplênicas/patologia
Neoplasias Esplênicas/radioterapia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009718



página 1 de 4530 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde